Developer docs
API playgroundTry for free, no card

Search company profiles

Alta Life Sciences

Full company profile

uuid0006hng

Namestring
Alta Life Sciences
Websiteurl
altals.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Alta Life Sciences is a Barcelona-based, multistage venture capital investment firm focused on the life sciences sector, founded in 2016. The firm operates with a small team (1-10 employees) and is positioned within the Iberian and broader European biotech investment ecosystem, as evidenced by its participation as an existing investor in Ona Therapeutics' $86.6 million oversubscribed Series B financing round alongside a syndicate of leading life sciences investors including Columbus Venture Partners, Mérieux Equity Partners, Ysios Capital, Asabys Partners, Bpifrance, CDTI, COFIDES, Korys, and FundPlus NV.

The firm's investment focus targets innovative biotechnology companies, with the Ona Therapeutics portfolio company developing antibody-drug conjugates (ADCs) for treatment-resistant cancers, specifically ONA-255 for breast cancer and ONA-389 for colorectal cancer. As a private, early- to growth-stage investor, Alta Life Sciences derives economics from traditional VC fund mechanics — management fees on committed capital and carried interest on exits — though specific fund sizes, AUM, portfolio composition beyond disclosed investments, and LP composition are not visible in the source data.

Public disclosures on the firm's operations are minimal; the available data captures the firm solely through its investee relationship with Ona Therapeutics. No founding partners, leadership team, fund vintages, or broader portfolio companies are described in the source material, limiting deeper assessment of strategy, track record, or organizational structure.

Short descriptiontext

Alta Life Sciences is a Barcelona-based, multistage venture capital investment firm founded in 2016, focused on the life sciences sector in Spain and broader Europe, with a small team operating alongside leading European biotech investors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
venture capital investing, life sciences investment, biotech venture capital, healthcare growth capital, multistage venture funding
Industry2 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANACAA
Technology & Software Growth Equity
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Venture Capital
Social media profiles1 record
Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Alta Life Sciences is a Barcelona-based venture capital firm that invests across multiple stages in life sciences and biotechnology companies. The firm provides growth capital to therapeutics developers, as evidenced by its participation as an existing investor in Ona Therapeutics' $86.6 million oversubscribed Series B financing round in June 2026, alongside other institutional healthcare investors.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Multistage Life Sciences Venture Capital Fund
CategoryVenture Capital / Life Sciences Investment
Description

A venture capital fund vehicle that provides growth-stage equity capital to life sciences and biotechnology companies, including oversubscribed Series B financings targeting therapeutic platforms such as antibody-drug conjugates. Intended for private biotech and life sciences companies seeking institutional investment partners.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spanish multistage life sciences VC firm headquartered in Barcelona/San Sebastián. Co-invested alongside Alta Life Sciences in Ona Therapeutics' Series B; most directly comparable peer by geography, fund size, and biotech focus.

TypeDirect peer
Description

Barcelona-based venture capital firm investing in life sciences (biopharma, medtech, digital health). Co-invested in Ona Therapeutics' Series B; directly comparable as a Spanish life sciences specialist VC.

TypeDirect peer
Description

Spanish venture capital manager specialised in life sciences, co-led Ona Therapeutics' $86.6M Series B. Directly comparable as a Spanish biotech VC with similar stage and sector focus.

TypeDirect peer
Description

Lyon-based growth equity firm dedicated to healthcare and life sciences, co-led the Ona Therapeutics Series B. Directly comparable as a European life sciences investor with cheque sizes overlapping Alta's.

TypeDirect peer
Description

Paris-based venture capital firm investing across the life sciences value chain (biotech, medtech, digital health). Directly comparable as a European specialist life sciences VC.

TypeDirect peer
Description

One of Europe's largest life sciences-dedicated VCs, active across biotech and medtech. Directly comparable as a European life sciences specialist with multistage strategy.

TypeDirect peer
Description

Dutch life sciences VC firm backing late-stage biotech and medical companies. Directly comparable as a European life sciences specialist investing at venture and growth stages.

TypeDirect peer
Description

Nordic/European life sciences venture capital investor active in therapeutics and medtech. Directly comparable as a European biotech-focused multistage VC.

9EQT Life Sciences (formerly LSP)
TypeDirect peer
Description

Amsterdam-based life sciences investor (now part of EQT) covering venture and growth stages in biotech and medtech. Directly comparable as a European life sciences specialist VC with similar stage and ticket sizes.

TypeBroad incumbent
Description

France's public investment bank with large life sciences activities across venture, growth, and direct equity. Co-invested in Ona Therapeutics' Series B; broad incumbent providing capital at scale across the European life sciences stack.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment18 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alta Life Sciences

Life Sciences Venture Capitalaltals.com

Alta Life Sciences is a Barcelona-based, multistage venture capital investment firm founded in 2016, focused on the life sciences sector in Spain and broader Europe, with a small team operating alongside leading European biotech investors.

What Alta Life Sciences does

Alta Life Sciences is a Barcelona-based, multistage venture capital investment firm focused on the life sciences sector, founded in 2016. The firm operates with a small team (1-10 employees) and is positioned within the Iberian and broader European biotech investment ecosystem, as evidenced by its participation as an existing investor in Ona Therapeutics' $86.6 million oversubscribed Series B financing round alongside a syndicate of leading life sciences investors including Columbus Venture Partners, Mérieux Equity Partners, Ysios Capital, Asabys Partners, Bpifrance, CDTI, COFIDES, Korys, and FundPlus NV.

The firm's investment focus targets innovative biotechnology companies, with the Ona Therapeutics portfolio company developing antibody-drug conjugates (ADCs) for treatment-resistant cancers, specifically ONA-255 for breast cancer and ONA-389 for colorectal cancer. As a private, early- to growth-stage investor, Alta Life Sciences derives economics from traditional VC fund mechanics — management fees on committed capital and carried interest on exits — though specific fund sizes, AUM, portfolio composition beyond disclosed investments, and LP composition are not visible in the source data.

Public disclosures on the firm's operations are minimal; the available data captures the firm solely through its investee relationship with Ona Therapeutics. No founding partners, leadership team, fund vintages, or broader portfolio companies are described in the source material, limiting deeper assessment of strategy, track record, or organizational structure.

Alta Life Sciences firmographics

Firmographics
Name
Alta Life Sciences
Website
https://altals.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Alta Life Sciences is a Barcelona-based, multistage venture capital investment firm founded in 2016, focused on the life sciences sector in Spain and broader Europe, with a small team operating alongside leading European biotech investors.
Ownership category
akta.pro rank

Alta Life Sciences industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANACAA
Technology & Software Growth Equity

Keywords

  • Venture capital investing
  • Life sciences investment
  • Biotech venture capital
  • Healthcare growth capital
  • Multistage venture funding

Where Alta Life Sciences is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Markets served

Alta Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Alta Life Sciences product offering

Product offering

Core offering

Alta Life Sciences is a Barcelona-based venture capital firm that invests across multiple stages in life sciences and biotechnology companies. The firm provides growth capital to therapeutics developers, as evidenced by its participation as an existing investor in Ona Therapeutics' $86.6 million oversubscribed Series B financing round in June 2026, alongside other institutional healthcare investors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Multistage Life Sciences Venture Capital Fund A venture capital fund vehicle that provides growth-stage equity capital to life sciences and biotechnology companies, including oversubscribed Series B financings targeting therapeutic platforms such as antibody-drug conjugates. Intended for private biotech and life sciences companies seeking institutional investment partners.

Companies that use Alta Life Sciences

Customer profile

Ideal customer profiles1 record

Alta Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Alta Life Sciences partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Alta Life Sciences competitors and assessment

Company assessment

Direct peers

  • Ysios Capital: Spanish multistage life sciences VC firm headquartered in Barcelona/San Sebastián. Co-invested alongside Alta Life Sciences in Ona Therapeutics' Series B; most directly comparable peer by geography, fund size, and biotech focus.
  • Asabys Partners: Barcelona-based venture capital firm investing in life sciences (biopharma, medtech, digital health). Co-invested in Ona Therapeutics' Series B; directly comparable as a Spanish life sciences specialist VC.
  • Columbus Venture Partners: Spanish venture capital manager specialised in life sciences, co-led Ona Therapeutics' $86.6M Series B. Directly comparable as a Spanish biotech VC with similar stage and sector focus.
  • Mérieux Equity Partners: Lyon-based growth equity firm dedicated to healthcare and life sciences, co-led the Ona Therapeutics Series B. Directly comparable as a European life sciences investor with cheque sizes overlapping Alta's.
  • Kurma Partners: Paris-based venture capital firm investing across the life sciences value chain (biotech, medtech, digital health). Directly comparable as a European specialist life sciences VC.
  • Sofinnova Partners: One of Europe's largest life sciences-dedicated VCs, active across biotech and medtech. Directly comparable as a European life sciences specialist with multistage strategy.
  • Forbion: Dutch life sciences VC firm backing late-stage biotech and medical companies. Directly comparable as a European life sciences specialist investing at venture and growth stages.
  • HealthCap: Nordic/European life sciences venture capital investor active in therapeutics and medtech. Directly comparable as a European biotech-focused multistage VC.
  • EQT Life Sciences (formerly LSP): Amsterdam-based life sciences investor (now part of EQT) covering venture and growth stages in biotech and medtech. Directly comparable as a European life sciences specialist VC with similar stage and ticket sizes.

Broad incumbents

  • Bpifrance: France's public investment bank with large life sciences activities across venture, growth, and direct equity. Co-invested in Ona Therapeutics' Series B; broad incumbent providing capital at scale across the European life sciences stack.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Alta Life Sciences social profiles

Digital presence

Alta Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alta Life Sciences leadership team

Management profile

Number of profiles

Alta Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alta Life Sciences M&A and investment

M&A and investment

M&A

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alta Life Sciences

What does Alta Life Sciences do?

Alta Life Sciences is a Barcelona-based venture capital firm that invests across multiple stages in life sciences and biotechnology companies. The firm provides growth capital to therapeutics developers, as evidenced by its participation as an existing investor in Ona Therapeutics' $86.6 million oversubscribed Series B financing round in June 2026, alongside other institutional healthcare investors.

Is Alta Life Sciences a public or private company?

Alta Life Sciences is a private company. It is classified as unknown and is currently operating.

When was Alta Life Sciences founded?

Alta Life Sciences was founded in 2016. It employs 1 to 10 people.

Where is Alta Life Sciences based?

Alta Life Sciences is headquartered in Barcelona, Spain, in the Europe region.

Who are Alta Life Sciences's main competitors?

Direct peers on record are Ysios Capital, Asabys Partners, Columbus Venture Partners, Mérieux Equity Partners, Kurma Partners, Sofinnova Partners, Forbion, HealthCap and EQT Life Sciences (formerly LSP). Bpifrance is listed as a broad incumbent.

Does Alta Life Sciences have an API?

No public API is recorded for Alta Life Sciences.

What industry is Alta Life Sciences in?

Alta Life Sciences's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANACAA, Technology & Software Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestorsinhealthcareSpain: Ona Therapeutics raises US$86.6m Series B to advance First-in-Class ADCs into clinical developmentOna Therapeutics, a Spain-based biopharmaceutical company, closed an oversubscribed US$86.6m Series B financing. The round was co-led by new investors Columbus, with the funds intended to advance first-in-class ADCs into clinical development.Empresas de Capital Riesgo en EspaOna Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical DevelopmentOna Therapeutics closed an oversubscribed $86.6 million Series B, co-led by Columbus Venture Partners and Mérieux Equity Partners. The funds will advance ONA-255, a first-in-class ADC for breast cancer, and progress ONA-389 toward first-in-human studies for colorectal cancer.BioSpaceOna Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical DevelopmentOna Therapeutics closed an oversubscribed $86.6 million Series B financing co-led by Columbus Venture Partners and Mérieux Equity Partners. Proceeds will advance clinical development of its lead ADC ONA-255 in breast cancer and progress ONA-389 in colorectal cancer. The company retains full worldwide commercial rights to its assets.BioXconomyOna bags $86.6m to push cancer-fighting ADCs into human trialsBarcelona-based biotech Ona has closed an $86.6 million Series B financing round to advance its antibody drug conjugate (ADC) pipeline, with ONA-255 targeting breast cancer moving toward clinical proof of concept and ONA-389 for colorectal cancer progressing toward first-in-human studies. Columbus Venture Partners and Mérieux Equity Partners co-led the round, with full participation from existing investors including Alta Life Sciences, Asabys Partners, Bpifrance, CDTI, FundPlus NV, and Ysios Capital, plus new backing from COFIDES and Korys. The company noted that all existing investors participated, which it described as a measure of confidence in its science and team.Empresas de Capital Riesgo en EspaMediktor raises €11m round led by MTIP and the support of existing investor Alta Life SciencesMediktor raised €11 million in a financing round led by MTIP with Alta Life Sciences participating. The Spanish healthtech company's AI medical assistant has a 91.3% success rate in clinical trials and plans to expand in the US, Europe, and Latin America. The company aims to be the first AI symptom checker in a European hospital emergency room early next year.WebcapitalriesgoMediktor cierra una ronda de €11M liderada por Mtip. Acude también Alta LSMediktor has closed an €11 million funding round led by Mtip, with participation from Alta LS, to accelerate international expansion and refine its AI medical triage tools. This transaction represents the third-largest venture capital raise in Spain's healthcare sector history. The company plans to establish new offices in Europe and Latin America while continuing to serve clients such as Mapfre and DKV.Empresas de Capital Riesgo en EspaINBRAIN Neuroelectronics raises over €14M Series A led by Asabys Partners, Alta Life Sciences and CDTIINBRAIN Neuroelectronics raised €14.35M in a Series A led by Asabys Partners and Alta Life Sciences, with CDTI and international investors. The funding will bring its graphene-based neural interface to humans and consolidate graphene as a standard in neurotechnologies.Empresas de Capital Riesgo en EspaAlta Life Sciences leads an oversubscribed investment round into Inbiomotion to launch its diagnostic product in breast cancerAlta Life Sciences led an oversubscribed investment round into Inbiomotion to launch its diagnostic product for early-stage breast cancer. The company's MAF test identifies patients who benefit from bisphosphonate adjuvant treatment, improving survival. The funding will support regulatory and commercial development, with commercialization expected next year.Empresas de Capital Riesgo en EspaPeptomyc announces a new equity financing round of 11.4M€ led by AurorA Science and supported by Alta Life Sciences, HealthEquity, CDTI and business angelsPeptomyc completed an 11.4M€ equity financing round led by AurorA Science, with support from Alta Life Sciences, HealthEquity, CDTI, and business angels. The funds will advance its lead candidate OMO103, a cell-penetrating peptide targeting Myc, with the first patient expected in Q1 2021.UnquoteAlta Life Sciences, Kurma lead €3.5m series-A for DeepullAlta Life Sciences and Kurma Partners led a €3.5m series-A round for Barcelona-based biotech Deepull, with participation from Axis Participaciones and Sofimac Innovation. The funds will use the financing to improve technology and develop first prototypes for a sepsis diagnostic system.